NIDDK Payline 2026: R01 Odds and the $500K Rule
Updated 7 official sources
Quick Answer: NIDDK publishes no FY2026 payline. Its guidelines prioritize R01s that request an average under $500,000 a year in direct costs and PIs with little other support.
Full answer and how we checked it
NIH's Data Book shows NIDDK's new R01 success rate fell to 9.0% in FY2025 (253 of 2,823), from 16.3% in FY2024. A Grantsights pull of NIH RePORTER found 468 new NIDDK R01 and R37 awards in FY2026, up from 257 in FY2025.
This guide is for: diabetes, digestive, kidney, nutrition, obesity and hematology investigators who want the current NIDDK payline, are deciding how large an R01 budget to request, or are waiting on a score after FY2025's sharp drop in NIDDK funding odds.
Data note: Policy language is from NIDDK's FY2026 funding guidelines on grants.nih.gov, read October 1, 2026. Success rates are from NIH Data Book tables 206 and 217 (data last updated February 2026). Award counts, first-year direct costs, project lengths and notice dates are from a Grantsights pull of the NIH RePORTER API on October 1, 2026 (administering institute NIDDK; R01 and R37 award type 1, meaning new awards only; R56 all types; fiscal years 2024-2026). The same query can be rerun in NIH RePORTER.
In this guide
- NIDDK Payline Status: Priorities Instead of a Cutoff
- NIDDK R01 Success Rates: The FY2025 Drop
- Forward Funding and the FY2026 Rebound
- The $500,000 Rule in the Award Record
- Project Length: Toward a Four-Year Average
- R56 Bridge Awards at NIDDK Since FY2023
- When NIDDK Awards Arrive
- Career and Training Awards at NIDDK, FY2025
- What NIDDK's Guidelines Don't Tell You
- Request, Trim, or Wait: Decision Table
- Sources
- Related Guides
For the same measures at every institute, and the FY2026 budget rules each one publishes, see the NIH and NSF funding odds tracker.
NIDDK is the institute where the budget line now carries as much strategic weight as the score. The FY2026 guidelines say so directly, and FY2025's numbers show why: NIDDK cut its new R01 awards by about 40% in a single year.
From Manusights, our sister product
Applying for an R01 or R21? Manusights offers an AI critique of your application against NIH's published review criteria: $149 for a new R01 or R21, $199 for a resubmission. Back within 3 business days of your upload.
Order a grant reviewNIDDK Payline Status: Priorities Instead of a Cutoff
According to the NIDDK FY2026 funding guidelines (opens in a new tab), the institute weighs "peer review outcomes, alignment with priorities in the Strategic plan, alignment with NIH priorities, portfolio balance, and the investigator(s) other research support." The page gives no percentile. It does give 5 concrete rules that act like a payline's fine print:
| FY2026 NIDDK rule | Practical effect |
|---|---|
| R01s requesting an average under $500,000 direct costs per year are prioritized | Budget size can decide a borderline application |
| PIs with minimal other support get higher priority; substantial other support is deprioritized | Well-funded labs face a higher bar |
| Special emphasis on Early Stage Investigators, with full recommended periods when possible | ESI status is worth confirming before review |
| Only one award per eligible ESI receives special emphasis | A second ESI application competes at the standard level |
| Competing awards may be adjusted toward a 4-year average duration | Plan aims that survive a shorter award |
The guidelines also give extra consideration to first competing renewals from investigators who were ESIs on their initial NIDDK R01. The page notes that NIH now operates under a continuing resolution through December 11, 2026, so FY2027 rules may differ.
Get research funding calls by email
About once a week, we email open research funding calls with a real deadline, from federal agencies such as NIH and NSF, picked for research institutions. One click to unsubscribe.
No spam. Unsubscribe anytime.
NIDDK R01 Success Rates: The FY2025 Drop
NIH's success-rate tables (opens in a new tab) show how unusual FY2025 was at NIDDK. From FY2019 to FY2024, the combined R01 and R37 rate moved between 18% and 23%. Then it nearly halved.
| Fiscal year | R01 and R37 applications | Awards | Success rate |
|---|---|---|---|
| FY2019 | 2,623 | 481 | 18.3% |
| FY2020 | 2,603 | 585 | 22.5% |
| FY2021 | 2,836 | 594 | 20.9% |
| FY2022 | 2,628 | 494 | 18.8% |
| FY2023 | 2,687 | 554 | 20.6% |
| FY2024 | 2,824 | 529 | 18.7% |
| FY2025 | 3,160 | 330 | 10.4% |
Source: NIH Data Book table 206, with Grantsights adding new, renewal and revision rows together. For example, NIDDK received 2,823 new R01 applications in FY2025 and funded 253, against 413 of 2,529 a year earlier. Renewals fell from 39.3% (116 of 295) to 23.0% (77 of 335). Across all research project grants, table 217 shows NIDDK at 12.0% in FY2025, down from 20.5%.
Money didn't fall the same way. NIDDK's R01 and R37 funding rose from $305.2 million in FY2024 to $323.6 million in FY2025, and average funding per award jumped from $576,940 to $980,546. According to NIH's FY2025 by-the-numbers post (opens in a new tab), NIH-wide changes "were likely due in part to more awards being forward funded than previous years."
Forward Funding and the FY2026 Rebound
Grantsights checked NIDDK's award record for multi-year funded awards, which NIH pays in one budget period covering several years. In RePORTER, these show a budget period longer than 13 months.
| New NIDDK R01/R37 awards (RePORTER) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| New award records | 431 | 257 | 468 |
| Multi-year funded | 0 | 55 | 20 |
| Paid one year at a time | 431 | 202 | 448 |
In FY2025, 55 of 257 new NIDDK R01s, about one in five, were paid up front. Each of those used several years of money in one fiscal year. In FY2026 the count of new awards recovered to 468 while multi-year funded awards fell to 20. NIH's FY2026 fiscal policy notice (opens in a new tab) limits FY2026 multi-year obligations to the FY2025 level, and the appropriation rose 1%.
That funding trend is good news for FY2026 applicants, but it isn't a success rate. NIDDK's FY2025 count of new R01 applications, 2,823, was its highest since at least FY2015. If FY2026 brought a similar number, 468 new awards would put the new-application rate near 17%, still below FY2023's 18.5%.
The $500,000 Rule in the Award Record
The guidelines prioritize R01 applications averaging under $500,000 a year in direct costs. RePORTER reports first-year direct costs, which Grantsights read for every new NIDDK R01 and R37 award paid one year at a time:
| New NIDDK R01/R37, single-year budgets | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Median first-year direct cost | $394,341 | $456,538 | $494,336 |
| Awards under $500,000 direct | 362 of 431 (84%) | 149 of 202 (74%) | 294 of 448 (66%) |
| Median total award (direct plus indirect) | $608,691 | $711,260 | $749,434 |
Two honest caveats. First-year direct cost isn't the same as the multi-year average the policy uses, though modular and flat budgets keep them close. And RePORTER shows what NIDDK awarded, not what applicants requested, so it can't show how often a larger request lost.
Still, the pattern is useful. The median first-year direct cost climbed to just under $500,000 in FY2026, and a third of funded awards sat above it. The rule is a priority, not a ceiling. If your science needs $560,000 a year, request it with a clear justification. If it fits in $490,000, staying under the line removes one reason to pass over a borderline score. The modular budget guide covers how to build and justify each level.
Project Length: Toward a Four-Year Average
NIDDK may adjust competing awards to reach a 4-year average duration, while ESIs, program projects and clinical trials generally keep their full recommended periods. The FY2026 award record:
| Project period, new NIDDK R01/R37 (FY2026) | Awards |
|---|---|
| Five years | 256 |
| Four years | 175 |
| Three years | 31 |
| Two years or less | 6 |
Most awards still run five years, which fits a policy that protects ESI periods. A non-ESI applicant should assume the award may be shortened and say which aims come first.
R56 Bridge Awards at NIDDK Since FY2023
NIDDK says it "will consider interim support on a very limited case-by-case basis" through one- or two-year R56 awards for promising unfunded R01s. NIH's table 206 counts 41 NIDDK R56 awards in FY2023, 39 in FY2024 and 11 in FY2025. RePORTER shows 15 new R56 awards in FY2026 with a median total of $294,998.
NIH's success-rate definition (opens in a new tab) counts an unfunded R01 that becomes a funded R56 as a funded application. So a few NIDDK "successes" in the table are bridge awards, not R01s. Don't plan a lab budget around an R56; treat it as an outcome to ask about, not a strategy.
When NIDDK Awards Arrive
The award record also shows timing. In FY2025, 111 of 257 new NIDDK R01 notices (43%) went out in September, the last month of the fiscal year. FY2026 spread out more: 150 in August, 55 in September, 50 in February and 47 in May. A long wait after council isn't a rejection. It's also not a reason to delay an A1.
Career and Training Awards at NIDDK, FY2025
The R01 collapse didn't spread evenly. NIH's tables 203 and 204 show NIDDK's other mechanisms held up far better in FY2025:
| NIDDK mechanism, FY2025 | Awards / applications | Success rate |
|---|---|---|
| R21 | 13 / 129 | 10.1% |
| K01 | 31 / 97 | 32.0% |
| K08 | 21 / 58 | 36.2% |
| K23 | 29 / 80 | 36.3% |
| K99 | 14 / 65 | 21.5% |
| F31 | 47 / 254 | 18.5% |
| F32 | 24 / 91 | 26.4% |
NIDDK's K01 count actually rose, from 21 awards in FY2024 to 31. A junior investigator who isn't yet competitive for a $500,000 R01 has a stronger route through a K award, where NIDDK funded roughly a third of applications. The K award success-rate page shows how NIDDK compares with other institutes, and the R21 line is a warning: at 10.1%, it isn't a shortcut.
What NIDDK's Guidelines Don't Tell You
| Source | What it gives you | What's missing |
|---|---|---|
| NIDDK FY2026 guidelines | Budget priority, other-support rule, ESI rules, R56 bridge | How much each factor weighs against the score |
| NIH Data Book | Official applications, awards, success rates | FY2026, which isn't published yet |
| NIH RePORTER | Award sizes, lengths and notice months | Requests that weren't funded |
The trap is treating "no payline" as "no information." NIDDK told applicants exactly which budgets and which PIs it favors. Few institute pages are that specific.
Request, Trim, or Wait: Decision Table
| Your situation | Best next action |
|---|---|
| Budget plan averages $480,000-$520,000 direct | Decide on purpose whether to come in under $500,000 |
| PI holds substantial other NIH support | Expect deprioritization; make the non-overlap case explicit |
| ESI with two applications in play | Only one gets ESI emphasis; ask which the program officer expects to lead |
| Scored A0 from FY2025 that missed | Resubmit; FY2026 new-award counts recovered |
| First renewal of an R01 won as an ESI | Mention the renewal consideration to the program officer |
For the A1, use the resubmission guide and the score explainer. Compare NIDDK with the NHLBI payline page and the NCI payline page, and look for other metabolic and kidney funding in Grantsights grant search.
Sources
- NIDDK FY2026 funding policies and considerations (opens in a new tab)
- NIH Data Book success-rate tables (opens in a new tab) (tables 206 and 217)
- NIH success rate definition (opens in a new tab)
- NIH, Fiscal Year 2025 By the Numbers (opens in a new tab)
- NOT-OD-26-059, Notice of Fiscal Policies in Effect for FY 2026 (opens in a new tab)
- NIH RePORTER (opens in a new tab) and the RePORTER API (opens in a new tab)
Related Guides
Frequently Asked Questions
Does NIDDK have a payline in 2026?
NIDDK's FY2026 funding guidelines publish no percentile or score cutoff. They list the factors NIDDK weighs instead: peer review outcomes, alignment with its Strategic Plan and NIH priorities, portfolio balance, and the investigator's other research support.
What is the NIDDK $500,000 rule?
NIDDK's FY2026 guidelines say R01 applications requesting an average of less than $500,000 in direct costs per year will be prioritized. It's a priority, not a cap, so larger R01s can still be funded but start at a disadvantage.
What was the NIDDK R01 success rate in FY2025?
NIH Data Book table 206 shows NIDDK funded 253 of 2,823 new R01 applications in FY2025, a 9.0% success rate, down from 16.3% in FY2024. Competing renewals fell from 39.3% to 23.0%. R01 and R37 together fell from 18.7% to 10.4%.
How many R01s did NIDDK fund in FY2026?
A Grantsights pull of NIH RePORTER on October 1, 2026 found 468 new NIDDK R01 and R37 award records for FY2026, compared with 257 in FY2025 and 431 in FY2024. NIH hasn't published FY2026 application counts, so the FY2026 success rate isn't known yet.
Can NIDDK give me an R56 if my R01 just misses?
NIDDK says it will consider one- or two-year R56 bridge awards on a very limited, case-by-case basis. NIH's success-rate table shows 39 NIDDK R56 awards in FY2024 and 11 in FY2025, and RePORTER shows 15 new R56 awards in FY2026.
Last updated October 10, 2026. Corrected October 10, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
NCI Payline 2026: No Cutoff, Budget Cuts, R01 Odds
NCI dropped paylines for FY2026 and cuts new R01 budgets by 6.5% to 17%. NIH tables show NCI funded 6.9% of new R01 applications in FY2025.
NEI Payline 2026: No Cutoff and a 12.8% New R01 Rate
NEI publishes no FY2026 payline or score cutoff. Its new R01 success rate fell from 23.6% to 12.8% in FY2025, while renewals held at 32.6%. See the data.
NHLBI Payline FY2026: No Cutoff, R01 Odds and Data
NHLBI has no FY2026 payline. NIH tables show it funded 14.6% of new R01 applications in FY2025, and 585 new R01s appear in FY2026 RePORTER records.
NIA Payline 2026: No Cutoff, 5.0% New R01 Odds
NIA has published no payline since FY2024, when general R01s funded to the 16th percentile. Its new R01 success rate fell to 5.0% in FY2025. See the data.
NIBIB Payline 2026: No Cutoff and a 16.1% New R01 Rate
NIBIB has no FY2026 payline. It cuts parent R01 budgets 10% to 20% and caps them at 4 years. Its new R01 success rate was 16.1% in FY2025. See the data.
NICHD Payline 2026: No Cutoff, 14.1% New R01 Odds
NICHD publishes no payline. It funded 14.1% of new R01s in FY2025 and cuts new R01 budgets 14% on average. See the rules and five years of odds.